Posted inNews and Updates
AI in Clinical Trials: Accelerating Medical Innovation
Discover how AI is transforming clinical trials through predictive modeling, automated patient recruitment, and enhanced data accuracy for faster results.
Posted inNews and Updates
nPhase Debuts AI Platform to Accelerate Clinical Trials
nPhase has launched a new AI-powered platform designed to streamline clinical trial design, enhance data management, and accelerate drug development timelines.
Posted inNews and Updates
Novartis Myotonic Dystrophy Drug Fails Phase 3 Trial
Novartis’s Phase 3 trial for del-desiran fails to meet primary endpoints in patients with Myotonic Dystrophy Type 1, halting progress on the ASO therapy.
Posted inNews and Updates
AI Imaging Shows Promise in Improving IPF Trial Outcomes
New clinical trial data reveals how AI-powered imaging is transforming Idiopathic Pulmonary Fibrosis research and the development of the drug ENV101.
Posted inNews and Updates
SOT109 Clinical Trial: New CDH17-Targeting ADC for Colorectal
SOTIO has dosed the first patient in the CADENCIA-01 trial for SOT109, a CDH17-targeting ADC aimed at treating advanced colorectal cancer.
Posted inNews and Updates
ALS Breakthrough: PhenoNet Completes Phase IIb Drug Trial
PhenoNet concludes patient enrollment for its Phase IIb trial of PHENOGENE-1A, a promising investigative therapy for Amyotrophic Lateral Sclerosis (ALS).
Posted inNews and Updates
Guggenheim Names Top Biotech Pick Following Clinical Success
Guggenheim identifies a top biotech stock to watch following successful clinical trial results. Explore the impact on growth and market potential here.
Posted inNews and Updates
Ocugen Launches Phase 3 Trial for GA Gene Therapy
Ocugen has initiated a Phase 3 trial for its GA gene therapy. Learn how this breakthrough approach aims to treat advanced macular degeneration.
Posted inNews and Updates
FDA Secures CDER and CBER Leadership Amid Commissioner Wait
The FDA has finalized key leadership roles at CDER and CBER, ensuring regulatory stability and scientific continuity while awaiting a new commissioner.
Posted inNews and Updates
Paxalisib Study Begins for Recurrent Pediatric Brain Cancer
Kazia Therapeutics begins dosing in the PNOC035 study, testing paxalisib as a targeted therapy for aggressive, recurrent pediatric AT/RT brain tumors.